Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AT-108
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : $32.7 million
Deal Type : Series A Financing
Swedish Biotech Raises €30M for Gene Therapy in Solid Tumors
Details : The financing aims to support the ongoing development of the lead program AT-108. Currently, it is being evaluated in the preclinical trial studies for neoplasms in the form of tailored treatment.
Product Name : AT-108
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 14, 2024
Lead Product(s) : AT-108
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : $32.7 million
Deal Type : Series A Financing
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Organovo Holdings
Deal Size : $6.8 million
Deal Type : Financing
Novo Holdings Co-Leads EUR 6M Seed Financing in Asgard Therapeutics
Details : The financing will enable Asgard Therapeutics to expand pipeline of preclinical assets and build on making personalized cancer immunotherapies optimized to unique patient. Funds will be used to further develop personalized therapy programs for multiple o...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 11, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Organovo Holdings
Deal Size : $6.8 million
Deal Type : Financing
Reset All
